Theraclone Sciences Receives $14,000,000 Series B Funding Round

  • Feed Type
  • Date
    3/25/2013
  • Company Name
    Theraclone Sciences
  • Mailing Address
    1124 Columbia Street Seattle, WA 98104
  • Company Description
    Theraclone Sciences is a discovery-stage biotech developing novel therapeutic antibodies for the treatment of infectious disease and inflammation. Our proprietary discovery platform allows us to comprehensively screen and identify the rare antibodies that select individuals produce to successfully ward off disease.
  • Website
    http://www.Theraclone-Sciences.com
  • Transaction Type
    Debt, Venture Equity
  • Transaction Amount
    $14,000,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    The company will use the proceeds to help advance its clinical programs and support ongoing discovery projects.
  • M&A Terms
  • Venture Investor
    ARCH Venture Partners
  • Venture Investor
    Canaan Partners
  • Venture Investor
    MPM Capital
  • Venture Investor
    HealthCare Ventures
  • Venture Investor
    Alexandria Real Estate Equities
  • Venture Investor
    Amgen Ventures
  • Venture Investor
    Versant Ventures
  • Venture Investor
    MidCap Financial
  • Venture Investor
    Silicon Valley Bank